Skip to content

Effect of oxycodone hyperalgesia combined with bupivacaine liposomal intercostal nerve block on the quality of postoperative recovery in patients with VATS

Effect of oxycodone hyperalgesia combined with bupivacaine liposomal intercostal nerve block on the quality of postoperative recovery in patients with VATS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101430
Enrollment
Unknown
Registered
2025-04-24
Start date
2024-11-28
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

test group:In the experimental group, oxycodone 0.1 mg/kg was given intravenously 15 minutes before the start of surgery, while 266 mg of bupivacaine liposome was diluted with saline to a total volume
control subjects:In the control group, the same mL of saline as oxycodone was given intravenously 15 minutes before the start of the operation, while 0.25% bupivacaine solution was injected into the i

Sponsors

Affiliated Hospital of Jiangnan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective thoracoscopic lobectomy/segmental lung resection; 2. 18 years of age or older; 3. ASA classification I to III; 4. Able to understand the study protocol and provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Emergency or urgent surgery, previous history of thoracic surgery, history of chronic pain, history of neurological disease; 2. severe cardiac, hepatic, or renal insufficiency; 3. allergy to anaesthetics; 4. the patient has an active infection (e.g., pneumonia) or any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction); 5. the patient has been enrolled in another clinical trial in the past 4 weeks; 6. Any condition that, in the judgement of the investigator, is unstable or may jeopardise the safety of the subject and compliance with the study; 7. Pregnant or breastfeeding women; 8. Hypersensitivity to the study drug or prior serious adverse reaction.

Design outcomes

Primary

MeasureTime frame
QoR-15 score at 24 hours postoperatively;

Secondary

MeasureTime frame
QoR-15 score at 48 hours postoperatively;QoR-15 score at 72 hours postoperatively;VAS score at 6 hours postoperatively;VAS score at 24 hours postoperatively;VAS score at 48 hours postoperatively;VAS score at 72 hours postoperatively;Postoperative extubation time;Incidence of postoperative nausea and vomiting;Total postoperative opioid use;Number of postoperative remedial analgesia;Earliest time out of bed after surgery;Duration of postoperative drain retention;Length of hospitalisation;

Countries

China

Contacts

Public ContactXian Ding

Affiliated Hospital of Jiangnan University

2420155271@qq.com+86 187 0619 6275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026